In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $383.00. The company’s shares closed yesterday at $298.84.

Devarakonda covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Incyte. In addition to Truist Financial, Amgen also received a Hold from Barclays’s Carter Gould in a ...

New study from deCODE genetics/Amgen highlights the importance of BMI in pathogenesis of disease, suggesting that reducing BMI alone could lower ...